Market Place
Sourcing Support
ReCode Receives Funding from CF Foundation for Gene Therapies
18 Nov 2024 //
BUSINESSWIRE
ReCode Doses First Patient In CF Clinical Study
26 Sep 2024 //
BUSINESSWIRE
ReCode Therapeutics to Participate in Upcoming Investor Conferences
25 Sep 2024 //
BUSINESSWIRE
ReCode Receives U.S. FDA Orphan Drug Designation for RCT1100
27 Jun 2024 //
BUSINESSWIRE
FDA Approves Adbry Autoinjector fo Adults with Moderate-to-Severe (AD)
13 Jun 2024 //
BUSINESSWIRE
New Article Published in Science Highlights the Potential of ReCode Therapeutics
13 Jun 2024 //
BUSINESSWIRE
ReCode Therapeutics Appoints Dean Mitchell As Board Chair
13 May 2024 //
BUSINESSWIRE
ReCode Therapeutics to Participate in May Conferences
01 May 2024 //
BUSINESSWIRE
ReCode Announces First Participants Dosed in a Phase 1 Study of RCT2100
21 Feb 2024 //
BUSINESSWIRE
ReCode Therapeutics to Participate in February Conferences
20 Feb 2024 //
BUSINESSWIRE
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration
15 Feb 2024 //
PRESS RELEASE
ReCode CEO Shehnaaz Suliman eyes second half IPO opportunity
17 Jan 2024 //
FIERCE BIOTECH
ReCode Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy
03 Jan 2024 //
BUSINESSWIRE
ReCode Therapeutics to Participate in November Conferences
10 Nov 2023 //
BUSINESSWIRE
ReCode Therapeutics Announces Closing of Extension to Series B Financing
19 Sep 2023 //
BUSINESSWIRE
ReCode Therapeutics to Present at September Investor Conferences
07 Sep 2023 //
BUSINESSWIRE
ReCode Appoints Erica Jefferson as Senior Vice President of Corporate Affairs
10 Jul 2023 //
BUSINESSWIRE
ReCode Therapeutics to Present at Jefferies Healthcare Conference
02 Jun 2023 //
BUSINESSWIRE
ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D.
17 Apr 2023 //
BUSINESSWIRE
ReCode Therapeutics to Present at Guggenheim Healthcare Talks
27 Mar 2023 //
BUSINESSWIRE
ReCode to Present at BMO Biopharma Spotlight Series
21 Mar 2023 //
BUSINESSWIRE
ReCode Announces First Participants Dosed in a Phase 1 Trial of RCT1100
15 Mar 2023 //
BUSINESSWIRE
Recode Therapeutics Appoints April Loui as Senior Vice President
01 Feb 2023 //
BUSINESSWIRE
ReCode Announces Strategic Investment from the Cystic Fibrosis Foundation
10 Jan 2023 //
BUSINESSWIRE
Asklepios partners with ReCode on gene-editing platform
10 Jan 2023 //
PHARMACEUTICAL-TECHNOLOGY
AskBio to Collaborate with ReCode for Single Vector Gene Editing Platform
09 Jan 2023 //
PR NEWSWIRE
ReCode Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
BUSINESSWIRE
ReCode Therapeutics Appoints Trisha Millican to Board of Directors
01 Dec 2022 //
BUSINESSWIRE
ReCode Therapeutics to Present at Upcoming Investor Conferences in 2022
22 Nov 2022 //
BUSINESSWIRE
ReCode Therapeutics Establishes Scientific Advisory Board
14 Nov 2022 //
BUSINESSWIRE
ReCode Therapeutics to Participate in Upcoming November Investor Conferences
02 Nov 2022 //
BUSINESSWIRE
ReCode Therapeutics to Participate in Upcoming October Investor Conferences
29 Sep 2022 //
BUSINESSWIRE
ReCode Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit
22 Sep 2022 //
BUSINESSWIRE
ReCode to Present at Morgan Stanley 20th Annual Global Healthcare Conference
06 Sep 2022 //
BUSINESSWIRE
ReCode to Expand Next-Gen Delivery Platform and Diversify Genetic Medicines
29 Jun 2022 //
BUSINESSWIRE
ReCode breaks the mold with $120M financing, Big Pharma backing
28 Jun 2022 //
FIERCEBIOTECH
ReCode Therapeutics to Present at Jefferies Healthcare Conference
03 Jun 2022 //
BUSINESSWIRE
ReCode Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis
18 May 2022 //
BUSINESSWIRE
ReCode Presents Preclinical Data from Inhaled mRNA Therapeutic Program
15 May 2022 //
BUSINESSWIRE
ReCode Therapeutics to Present at 2022 RBC Capital Markets Conference
10 May 2022 //
BUSINESSWIRE
ReCode Tx to Present PC Data Using Proprietary SORT LNP Delivery Platform
03 May 2022 //
BUSINESSWIRE
ReCode Tx to Present at Oppenheimer 32nd Annual Healthcare Conference
09 Mar 2022 //
BUSINESSWIRE
ReCode Therapeutics to Present at 40th JPM Conference
10 Jan 2022 //
BUSINESSWIRE
After Moderna success, Flagship`s next RNA bet: $50M for Alltrna
10 Nov 2021 //
YAHOOFINANCE
ReCode Therapeutics Presents Preclinical Data from mRNA-based Cystic Fibrosis
03 Nov 2021 //
BUSINESSWIRE
ReCode snags $80M from Pfizer, Sanofi for mRNA work in CF, lungs
22 Oct 2021 //
MEDCITYNEWS
ReCode Therapeutics to Present Preclinical Data from mRNA-based Program
19 Oct 2021 //
BUSINESSWIRE
ReCode Appoints Nicholas P. France as Senior VP of Clinical Development
27 Sep 2021 //
BUSINESSWIRE
ReCode Therapeutics Announces Participation in Upcoming Investor Conferences
03 Sep 2021 //
BUSINESSWIRE
ReCode Therapeutics Announces Participation in Upcoming Investor Conferences
03 Sep 2021 //
BUSINESSWIRE
ReCode Therapeutics Appoints Angèle Maki as Senior V.P, Business Development
16 Aug 2021 //
BUSINESSWIRE
ReCode Presents Encouraging Preclinical Data from Inhaled mRNA Therapeutics
05 Aug 2021 //
BUSINESSWIRE
ReCode Therapeutics to Participate in Upcoming August Investor Conferences
04 Aug 2021 //
BUSINESSWIRE
ReCode to Presents Data from mRNA-Based Program for Primary Ciliary Dyskinesia
30 Jul 2021 //
BUSINESS WIRE
ReCode Therapeutics to Present at William Blair Biotech Focus Conference 2021
07 Jul 2021 //
BUSINESSWIRE
ReCode Therapeutics to Participate in Upcoming June Investor Conferences
14 Jun 2021 //
BUSINESSWIRE
ReCode Therapeutics Presents Preclinical Data Using SORT-LNP
11 Jun 2021 //
BUSINESSWIRE
ReCode Therapeutics Presents Preclinical Data Using SORT-LNP
11 Jun 2021 //
BUSINESSWIRE
ReCode to Present Preclinical Data Using SORT-LNP™ and RNA Platforms
24 May 2021 //
BUSINESSWIRE
